GlassScriptPhysician profile
Akm M Hossain
NPI 1023111572
$6,362.97
in general payments reported to CMS, 2019-2025
61 companies · $2,617 in 2025
The $2,617 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $401 · 2020: $239 · 2021: $464 · 2022: $358 · 2023: $543 · 2024: $1,739 · 2025: $2,617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,878 · Education: $21.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,878.22 |
| Education | $21.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $798.99 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Novartis Pharmaceuticals Corporation | $556.84 | 2019-2025 | |
| Pfizer INC. | $480.97 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $319.06 | 2022-2025 | Enhertu, Imfinzi, Lynparza |
| Janssen Biotech, INC. | $288.51 | 2023-2025 | Erleada, Rybrevant, Balversa |
| Gilead Sciences, INC. | $237.06 | 2024-2025 | Trodelvy |
| Astellas Pharma US INC | $222.64 | 2024-2025 | Vyloy, Padcev, Xospata |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.11 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $187.74 | 2022-2024 | Libtayo |
| Fennec Pharmaceuticals, INC. | $181.00 | 2024-2025 | Fyarro, Pedmark |
| Incyte Corporation | $177.41 | 2024-2025 | Jakafi, Monjuvi, Zynyz |
| Puma Biotechnology, INC. | $167.80 | 2020-2025 | |
| Pharmacosmos Therapeutics INC. | $153.91 | 2021-2025 | Monoferric |
| Array Biopharma INC | $140.65 | 2020-2025 | Braftovi, Mektovi, Tukysa |
| Pharmaessentia USA Corporation | $136.66 | 2024-2025 | Besremi |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $134.16 | 2024-2025 | |
| Celgene Corporation | $133.57 | 2023-2024 | Reblozyl, Pomalyst |
| Glaxosmithkline, LLC. | $106.44 | 2024-2025 | Ojjaara |
| Taiho Oncology, INC. | $105.15 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $95.21 | 2020-2025 | |
| Ethicon US, LLC | $86.60 | 2019-2020 | |
| Lilly USA, LLC | $80.40 | 2020-2025 | Verzenio, Jaypirca, Retevmo |
| Global Blood Therapeutics, INC. | $77.49 | 2021-2022 | |
| Tersera Therapeutics LLC | $74.16 | 2019 | |
| Beone Medicines USA, INC. | $73.41 | 2025 | Tevimbra, Brukinsa |
| Sumitomo Pharma America, INC. | $65.71 | 2024-2025 | Orgovyx |
| Caris Mpi, INC. | $57.40 | 2025 | Mi Cancer Seek |
| Bayer Healthcare Pharmaceuticals INC. | $54.42 | 2025 | |
| Genzyme Corporation | $51.13 | 2021-2024 | |
| Stemline Therapeutics INC. | $47.68 | 2024 | Orserdu |
| Genentech USA, INC. | $47.06 | 2025 | Venclexta |
| Rigel Pharmaceuticals, INC. | $45.18 | 2019-2024 | Rezlidhia, Tavalisse |
| Tempus Ai, INC | $44.68 | 2024 | Xt Cdx |
| Janssen Scientific Affairs, LLC | $41.67 | 2025 | Darzalex, Talvey, Tecvayli |
| Sobi, INC | $41.64 | 2024 | |
| Merck Sharp & Dohme LLC | $38.76 | 2021-2025 | Keytruda |
| Karyopharm Therapeutics INC. | $36.88 | 2024 | Xpovio |
| Kite Pharma, INC. | $33.48 | 2025 | Yescarta |
| Seagen INC. | $32.71 | 2021 | |
| Novocure INC. | $32.45 | 2025 | Optune Lua (Novottf-200t) |
| Takeda Pharmaceuticals U.S.A., INC. | $31.52 | 2024 | Fruzaqla |
| Menarini Silicon Biosystems, INC. | $29.47 | 2025 | |
| Genmab U.S., INC. | $28.31 | 2024 | Epkinly |
| Baxter Healthcare | $28.20 | 2023 | Tisseel |
| Legend Biotech USA INC. | $27.16 | 2025 | Carvykti |
| Csl Behring | $26.60 | 2025 | Idelvion, Afstyla |
| Beigene USA, INC. | $25.67 | 2025 | Brukinsa |
| E.R. Squibb & Sons, L.L.C. | $23.62 | 2025 | Opdivo |
| Spectrum Pharmaceuticals INC. | $23.47 | 2024 | Rolvedon |
| Springworks Therapeutics, INC. | $23.31 | 2024 | Ogsiveo |
| Alexion Pharmaceuticals, INC. | $21.88 | 2025 | Ultomiris |
| Deciphera Pharmaceuticals INC. | $20.94 | 2024 | Qinlock |
| Eisai INC. | $20.84 | 2024 | |
| Servier Pharmaceuticals LLC | $20.75 | 2025 | |
| Acell, INC. | $20.60 | 2019 | |
| Sirtex Medical INC | $20.59 | 2024 | Sir-Spheres Microspheres |
| Exelixis INC. | $20.02 | 2024 | Cabometyx |
| Smith+Nephew, INC. | $19.90 | 2021 | |
| Amgen INC. | $19.46 | 2019 | |
| Amag Pharmaceuticals, INC. | $17.00 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $15.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Akm Hossain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.